APLS
NASDAQ
US
Apellis Pharmaceuticals, Inc. - Common Stock
$40.41
▲ +$0.02
(+0.05%)
Vol 10.3M
8
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$3.2B
P/E
70.7
ROE
18.9%
Margin
4.4%
D/E
113.34
Beta
0.29
52W
$16–$36
Wall Street Consensus
27 analysts · Apr 20263
Strong Buy
9
Buy
15
Hold
0
Sell
0
Strong Sell
44.4%
Buy Rating
Price Chart
Similar Stocks
PTCT
PTC Therapeutics Inc
P/E 8.1
$6.1B
ERAS
Erasca Inc
$1.1B
CAI
Caris Life Sciences Inc
$7.6B
CELC
Celcuity Inc
$4.6B
TGTX
TG Therapeutics Inc
P/E 10.6
$4.7B
IMVT
Immunovant Inc
$5.1B
APGE
Apogee Therapeutics Inc
$5.2B
DNTH
Dianthus Therapeutics Inc
$1.8B
FOLD
Amicus Therapeutics Inc
$4.4B
VKTX
Viking Therapeutics Inc
$4.0B
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.39 | $-0.47 | $-0.08 |
| Sep 2025 | $1.21 | $1.67 | +$0.46 |
| Jun 2025 | $-0.48 | $-0.33 | +$0.15 |
| Mar 2025 | $-0.37 | $-0.74 | $-0.37 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -116.1% | -116.1% | -116.1% | -116.1% | 18.9% | 18.9% |
| P/E (TTM) | — | — | — | — | 58.84 | 70.65 |
| Net Margin | -23.6% | -30.2% | -30.2% | -30.2% | 4.4% | 4.4% |
| Gross Margin | 92.4% | 83.8% | 83.8% | 83.8% | 88.8% | 88.8% |
| D/E Ratio | 290.48 | 290.48 | 290.48 | 290.48 | 113.34 | 113.34 |
| Current Ratio | 3.77 | 3.77 | 3.77 | 3.77 | 3.54 | 3.54 |
Key Ratios
ROA (TTM)
5.0%
P/S (TTM)
3.13
P/B
17.4
EPS (TTM)
$0.30
CF/Share
$-5.21
Rev Growth 3Y
+127.2%
52W High
$35.57
52W Low
$16.10
$16.10
52-Week Range
$35.57
How does APLS compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
APLS valuation vs Biotechnology peers
P/E ratio
70.7
▲
276%
above
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
3.1
▼
76%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
17.4
▲
606%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
APLS profitability vs Biotechnology peers
ROE
18.9%
▲
128%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
4.4%
▲
102%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
88.9%
▲
13%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
5.0%
▲
111%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
APLS financial health vs Biotechnology peers
D/E ratio
113.3
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
3.5
▼
20%
below
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
0.3
▼
71%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
APLS fundamentals radar
APLS
Peer median
Industry
APLS profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
APLS vs peers: key metrics
Latest News
Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase …
Yahoo Finance · Apr 02
Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio
Yahoo Finance · Apr 02
Noteworthy Tuesday Option Activity: APLS, AMTM, EXP
Nasdaq · Mar 31
This New $193 Million Bet Targets a Biotech With $689 Million in …
Nasdaq · Mar 22